Sector News

Lilly Announces Promotion of Darren J. Carroll to Senior VP of Corporate Business Development

January 5, 2015
Life sciences

/PRNewswire/ – Eli Lilly and Company today announced the promotion of Darren J. Carroll to Senior Vice President of Corporate Business Development effective Jan. 1, 2015. He has been the Vice President of Corporate Business Development since 2010.

During his 18-year career at Lilly, Carroll has helped to lead and/or created new business models for the company, including e-Lilly, InnoCentive, Lilly Ventures, and Lilly Asia Ventures. He was the driver behind the company’s Capital Funds Portfolio strategy with several venture capital fund managers, which has thus far led to the creation of 11 new companies — including Artaeus, which Lilly acquired in January 2014 — aimed at developing novel molecules to clinical proof of concept. In his new role, Carroll will be responsible for all strategic corporate transactions including mergers and acquisitions, joint ventures, business collaborations, private equity investments, and out-partnering.  Carroll will report to Derica Rice, Lilly’s Executive Vice President of Global Services and CFO. 

“As we aim to ensure a more continuous flow of first-or best-in-class medicines in the years ahead, we must, and we will, increase our business development activity – through partnerships, licensing, and acquisitions,” said Rice. “Darren is the ideal candidate to lead this important and increasingly competitive work. He’s a pragmatic, creative individual with an extraordinary bandwidth for managing and understanding complex business opportunities. Darren’s high integrity, insights into diverse markets and cultures, and unique experiences, both inside and outside of Lilly, are important assets as we seek to be more attractive to potential partners.”  

Carroll offered the following on Lilly’s approach to business development, “The companies that are most effective at external innovation leverage a strong internal innovation capability.  Our long term commitment to scientific excellence at Lilly is the foundation for success in  identifying, accessing and shaping external innovation.  It’s been recognized by partners that range from start-ups to other top 10 pharmaceutical companies, and it’s a critical reason why we’re attractive as a partner: We’re ‘all in’ on innovation.”

Source: Eli Lilly and Company

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend